Volume 4.19 | May 20

Cancer Stem Cell News 4.19 May 20, 2015
Cancer Stem Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CSCN on Twitter
 
TOP STORY
C8orf4 Negatively Regulates Self-Renewal of Liver Cancer Stem Cells via Suppression of NOTCH2 Signaling
Scientists found that C8orf4 is weakly expressed in hepatocellular carcinoma tumors and liver cancer stem cells (CSCs). C8orf4 attenuated the self-renewal capacity of liver CSCs and tumor propagation. [Nat Commun] Full Article
Request your FREE copy of STEMCELL Technologies' new 2015 catalog!
 
PUBLICATIONS (Ranked by impact factor of the journal)
Quantifying the Landscape for Development and Cancer from a Core Cancer Stem Cell Circuit
The authors developed a landscape and path theoretical framework to investigate the global natures and dynamics for a core cancer stem cell gene network. The landscape exhibits four basins of attraction, representing cancer stem cell, stem cell, cancer and normal cell states. They also uncovered certain key genes and regulations responsible for determining the switching between different states. [Cancer Res] Abstract

IMP3 Promotes Stem-Like Properties in Triple-Negative Breast Cancer by Regulating SLUG
Scientists observed that insulin-like growth factor-2 mRNA binding protein 3 (IMP3) expression is significantly higher in tumor initiating than in non-tumor initiating breast cancer cells and demonstrated that IMP3 contributes to self-renewal and tumor initiation, properties associated with cancer stem cells. [Oncogene] Abstract

Type II Transglutaminase Stimulates Epidermal Cancer Stem Cell Epithelial-Mesenchymal Transition
Researchers investigated the role of type II transglutaminase (TG2) in regulating epithelial mesenchymal transition (EMT) in epidermal cancer stem cells. They showed that TG2 knockdown or treatment with TG2 inhibitor, resulted in a reduced EMT marker expression, and reduced cell migration and invasion. [Oncotarget] Full Article

CD24+ Ovarian Cancer Cells are Enriched for Cancer Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Investigators showed that CD24+ and CD133+ cells have increased tumorsphere forming capacity. CD133+ cells demonstrated a trend for increased tumor initiation while CD24+ cells vs CD24 cells, had significantly greater tumor initiation and tumor growth capacity. [Mol Cancer Ther] Abstract

EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA
Researchers designed and synthesized a novel anti-epithelial cell adhesion molecule (EpCAM)-monoclonal-antibody-labeled cancer stem cells (CSCs)-targeting, noncytotoxic and pH-sensitive block copolymer vesicle as a nano-carrier of anticancer drug and siRNA. [Biomacromolecules] Abstract

Survival of Skin Cancer Stem Cells Requires the Ezh2 Polycomb Group Protein
Investigators showed that Ezh2 is required for epidermal cancer stem (ECS) cell survival, migration, invasion and tumor formation, and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. They also showed that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduced Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. [Carcinogenesis] Abstract

Inhibition of STAT3, FAK and Src Mediated Signaling Reduces Cancer Stem Cell Load, Tumorigenic Potential and Metastasis in Breast Cancer
Scientists evaluated the effects of Shikonin (Shk) on breast cancer and found its anti-cancer stem cell (CSC) potential. Shk treatment decreased the expression of various epithelial to mesenchymal transition and CSC associated markers. [Sci Rep] Full Article

Ovatodiolide Sensitizes Aggressive Breast Cancer Cells to Doxorubicin Anticancer Activity, Eliminates Their Cancer Stem Cell-Like Phenotype, and Reduces Doxorubicin-Associated Toxicity
Investigators evaluated the usability of ovatodiolide (Ova) in sensitizing triple negative breast cancer (TNBC) cells to doxorubicin (Doxo), cytotoxicity, so as to reduce Doxo effective dose and consequently its adverse effects. Ova-sensitized TNBC cells also lost their cancer stem cell-like phenotype evidenced by significant dissolution and necrosis of formed mammospheres, as well as their terminal differentiation. [Cancer Lett] Abstract

Glabridin Inhibits Cancer Stem Cell-Like Properties of Human Breast Cancer Cells: An Epigenetic Regulation of miR-148a/SMAd2 Signaling
The authors report that glabridin (GLA) attenuated the cancer stem cell (CSC)-like properties through microRNA-148a (miR-148a)/transforming growth factor beta-SMAD2 signal pathway in vitro and in vivo. In MDA-MB-231 and Hs-578T breast cancer cell lines, GLA enhanced the expression of miR-148a through DNA demethylation. [Mol Carcinog] Abstract

Ginsenoside Rh2 Inhibits Cancer Stem-Like Cells in Skin Squamous Cell Carcinoma
The effects of ginsenoside Rh2 (GRh2) on Lgr5-positive cancer stem cells (CSCs) were determined by flow cytometry and by tumor sphere formation. Scientists found that GRh2 dose-dependently reduced skin squamous cell carcinoma viability, possibly through reduced the number of Lgr5-positive CSCs. [Cell Physiol Biochem] Full Article

Standardize Your CFU Assays With STEMvision for Automated CFU Assay Imaging and Analysis
 
REVIEWS
Normal vs Cancer Thyroid Stem Cells: The Road to Transformation
The authors discuss new insights into thyroid stem cells as a potential source of cancer formation in light of the available information on the oncogenic role of genetic modifications that occur during thyroid cancer development. Understanding the fine mechanisms that regulate tumor transformation may provide new ground for clinical intervention in terms of prevention, diagnosis and therapy. [Oncogene] Abstract

Cancer Stem Cells: A Potential Target for Cancer Therapy
The identification of cancer stem cells (CSCs) and a better understanding of the complex characteristics of CSCs will provide invaluable diagnostic, therapeutic and prognostic targets for clinical application. The authors introduce the dysregulated properties of CSCs in cancers and discuss the possible challenges in targeting CSCs for cancer treatment. [Cell Mol Life Sci] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
SCIENCE NEWS
Australian Studies Confirm TRXE-009 Kills Resistant Pediatric Brain Cancer Cells
Novogen Limited released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable pediatric brain cancer called diffuse intrinsic pontine glioma. [Press release from Novogen Limited discussing research presented at the 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research, San Diego] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture.
Watch now.
 
INDUSTRY NEWS
Fred Hutch and Uganda Cancer Institute Open UCI-Fred Hutch Cancer Centre in Kampala
Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute will open the UCI-Fred Hutch Cancer Centre in Kampala, the first comprehensive cancer center jointly constructed by U.S. and African cancer institutions in sub-Saharan Africa. [Fred Hutchinson Cancer Research Center (Newswise, Inc)]
Press Release
| Video

NHS Pressures at Risk of Stifling Cancer Research
Daily pressures on the NHS are having a serious impact on its ability to support world leading research into cancer, according to a Cancer Research UK commissioned report from the University of Birmingham. The report revealed pockets of excellence in clinical research, but also showed how escalating pressures to deliver routine NHS services are squeezing out time for hospital staff to do vital research. [Cancer Research UK] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cancer Diagnosis & Therapy Congress
September 3-4, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

PhD Student – Cancer Stem Cell Immunology (Cardiff University)

PhD Position – Neurology & Cancer Stem Cells (Cardiff University)

Postdoctoral Positions – Epigenetics, Stem Cells and Cancer (University of Copenhagen)

Postdoctoral Positions – Cancer Stem Cell Biology (Weill Cornell College of Medicine)

Postdoctoral Position – Cancer Research (INSERM)

Postdoctoral Fellow – Colon Cancer (Baylor Research Institute)

Postdoctoral Research Fellow – Cell Death of Normal Tissue Stem Cells & Cancer Stem Cells (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Cancer Biology (University of Pennsylvania)

Postdoctoral Fellow – Breast Cancer & Stem Cell Biology (University of Cincinnati)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us